Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (CDTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
CDTX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCidara Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 94.52% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | -$0.02B | -94.52% |
| 2023-12-31 | $0.02B | -$0.04B | -63.87% |
| 2022-12-31 | $0.06B | +$0.01B | +30.01% |
| 2021-12-31 | $0.05B | +$0.04B | +310.81% |
| 2020-12-31 | $0.01B | -$0.01B | -42.30% |
| 2019-12-31 | $0.02B | +$0.02B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare CDTX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cidara Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cidara Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Cidara Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CDTX revenue · 4 questionsCDTX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 94.52% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Cidara Therapeutics, Inc. SEC filings · GAAP · Cidara Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026